- Home
- MVSTW vs XOMAP Comparison
MVSTW vs XOMAP Comparison
Compare MVSTW & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | XOMAP |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 1921 | 13 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MVSTW | XOMAP |
|---|---|---|
| Price | $0.06 | $26.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 126.0K | N/A |
| Earning Date | 03-14-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $370,989,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.03 | N/A |
| 52 Week Low | $0.35 | N/A |
| 52 Week High | $0.44 | N/A |
Technical Indicators
Market Signals| Indicator | MVSTW | XOMAP |
|---|---|---|
| Relative Strength Index (RSI) | 34.80 | 40.38 |
| Support Level | $0.11 | $26.12 |
| Resistance Level | $0.11 | $26.51 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 31.63 | 0.92 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.